U.S. Supreme Court Schedules Oral Arguments on 340B Reimbursement Case

The Supreme Court’s decision to hear the case over Medicare-related 340B cuts to hospitals surprised many observers. Oral arguments are scheduled for Nov. 30, with a decision not likely until the spring.

The U.S. Supreme Court has announced the cases it will take up this fall and 340B will be on the plate. The court recently posted its hearings schedule for the months of October through December and will hear oral

Read More »

House GOP Conference Chair Stefanik Signs on to 340B Anti-Pickpocketing Bill

House Republican conference chair Elise Stefanik (R-NY) is the most high profile sponsor of date for the bipartisan 340B Protect Act.

U.S. House GOP Conference Chair Elise Stefanik (N.Y.), the third highest-ranking House Republican, has issued a news release and tweeted about signing on as a sponsor of bipartisan legislation prohibiting pharmacy benefit managers (PBMs) and other third-party payers from paying

Read More »

HHS Is Vetting OPA Director Applications and Apexus Is Seeking a New Senior VP For High-Profile Position

HRSA and its 340B government contractor are looking to fill two critically important positions including replacing Rear Admiral Krista Pedley who has recently been promoted from her position as OPA Director.

The federal government has started reviewing applications from individuals seeking to be the next Director of the U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA), the unit within HRSA that oversees the 340B program. Tuesday, Sept.

Read More »

“The Biggest Crisis Since 340B’s Inception:” 340B Report Leader Provides Input in New Podcast

In a new podcast, 340B Report Publisher and CEO Ted Slafsky provides input on key 340B challenges as well as some predictions.

The dispute with pharmaceutical firms over the use of contract pharmacies for 340B covered entities is the biggest crisis facing the program since its inception in the early 1990s, 340B Report CEO and Publisher Ted Slafsky tells “The Future of

Read More »

Biden Picks Academic with Hospital Connections to Run HHS Policy Shop

Robert Otto Valdez has been selected by President Biden for a key HHS policy position that impacts the 340B program.

President Biden announced last week that he plans to nominate public health expert Robert Otto Valdez to serve as U.S. Health and Human Services (HHS) Assistant Secretary for Planning and Evaluation (ASPE).

Please Login or Become

Read More »

North Carolina Enacts PBM Oversight Law Protecting Most 340B Covered Entities

North Carolina Gov. Roy Cooper (D) recently signed into law a new bill that gives some 340B covered entities protection from so-called discriminatory reimbursement cuts and restrictive contracting terms. Photo credit: Gov. Roy Cooper's office via Twitter.

North Carolina Gov. Roy Cooper (D) signed into law yesterday a bill that imposes greater oversight of pharmacy benefit managers and protects most categories of 340B entities from so called discriminatory reimbursement and contracting practices.


Read More »

The Power of Partnership: Work with an Administrator that Understands Independent Pharmacies


It is my pleasure to introduce our company to 340B Report’s readers. RxPreferred Benefits is a fully transparent 340B Administrator and Pharmacy Benefit Manager (PBM) founded, and solely owned, by independent pharmacy representatives. Privately held and headquartered in Nashville, TN, RxPreferred operates nationally, partnering with a wide range of clients including: 340B covered entities, self-funded employers, hospitals, health systems, hospices, pharmacies, brokers, and third-party administrators.

Zero Conflicts-of-Interest

Read More »

340B Hospitals Make Their Case to Supreme Court for Ending Deep Medicare Drug Payment Cuts

Hospital groups filed a brief with the U.S. Supreme Court on Friday in their lawsuit challenging the deep cut in 340B hospitals' Medicare Part B drug reimbursement.

Federal health officials “violated unambiguous statutory commands” in 2018 when they lowered lower Medicare Part B drug reimbursement rates for 340B hospitals by nearly 30% and their decision should be set aside, hospital groups and individual hospitals told the U.S.

Read More »

Evolving Payor Strategies to Control Spending on Specialty Medications


The challenges that ‘white bagging’ poses for patients and providers are gaining attention as more health plans mandate these policies. ‘White bagging’ disrupts traditional ‘buy-and-bill’ practices for provider-administered drugs, creating patient safety concerns, operational problems, and financial challenges for covered entities.

Impact of ‘White Bagging’ Policies on Covered Entities

In the traditional ‘buy-and-bill’ model, covered entities maintain control of the drug

Read More »
Generic selectors
Exact matches only
Search in title
Search in content